Stoke Therapeutics, Inc.STOKNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank38
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-7.67%
↑ 97% vs avg
Percentile
P38
Within normal range
Streak
2 yr
Consecutive growthExpanding
Average
-265.21%
Historical baseline
PeriodValueYoY Change
TTM-7.67%+97.2%
2024-271.36%+78.8%
2023-1279.09%-54.3%
2022-828.78%-
20210.00%-
20200.00%-
20190.00%-
20180.00%-
20170.00%-